Belinostat
Melphalan
Apaziquone
Raj Shrotriya, Spectrum’s chairman, president and CEO, likes to be an acquirer, analysts say. To boost the value of Spectrum’s stock, Shrotriya could enter into a merger agreement with a larger pharmaceutical company or acquire another drugmaker with an attractive product. He is confident that as a stand-alone company, Spectrum has the potential of becoming a larfger company with a bigger and diversified presence in the pharmaceutical industry.
Shrotriya says over the next 18 months, he expects Spectrum will be filing three new drug applications with the FDA — for Belinostat, a pan-HDAC inhibitor that could have the potential of becoming a backbone of chemotherapy along with carplatin and paclitaxel; Melphalan, a unique formulation used as a conditioning regimen for bone marrow transplant in certain diseases; and Apaziquone.
